Replimune Group (REPL) Competitors $5.49 -0.18 (-3.17%) Closing price 04:00 PM EasternExtended Trading$5.48 -0.01 (-0.18%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. IMCR, AUPH, CDTX, WVE, JANX, SDGR, EWTX, HROW, ARDX, and ETNBShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Harrow (HROW), Ardelyx (ARDX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Immunocore Aurinia Pharmaceuticals Cidara Therapeutics WAVE Life Sciences Janux Therapeutics Schrodinger Edgewise Therapeutics Harrow Ardelyx 89BIO Replimune Group (NASDAQ:REPL) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation. Is REPL or IMCR more profitable? Replimune Group has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Immunocore -5.70%-5.40%-1.93% Does the media prefer REPL or IMCR? In the previous week, Replimune Group had 25 more articles in the media than Immunocore. MarketBeat recorded 28 mentions for Replimune Group and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.51 beat Replimune Group's score of 0.09 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 2 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher valuation and earnings, REPL or IMCR? Immunocore has higher revenue and earnings than Replimune Group. Immunocore is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.69Immunocore$310.20M5.29-$51.09M-$0.40-81.48 Do institutionals and insiders have more ownership in REPL or IMCR? 92.5% of Replimune Group shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, REPL or IMCR? Replimune Group has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Do analysts prefer REPL or IMCR? Replimune Group presently has a consensus price target of $7.67, indicating a potential upside of 39.65%. Immunocore has a consensus price target of $56.89, indicating a potential upside of 74.56%. Given Immunocore's stronger consensus rating and higher probable upside, analysts clearly believe Immunocore is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.33Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 SummaryImmunocore beats Replimune Group on 11 of the 16 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$428.53M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.6920.9030.1925.84Price / SalesN/A387.71474.17122.81Price / CashN/A43.2325.7828.79Price / Book1.029.649.425.99Net Income-$247.30M-$54.08M$3.27B$265.29M7 Day Performance3.00%2.62%2.04%2.53%1 Month Performance74.29%4.05%3.58%0.92%1 Year Performance-45.86%9.48%30.08%18.70% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.4195 of 5 stars$5.49-3.2%$7.67+39.6%-44.1%$428.53MN/A-1.69210Gap DownIMCRImmunocore1.829 of 5 stars$32.31-1.7%$58.00+79.5%-7.9%$1.63B$310.20M-80.78320Positive NewsAnalyst ForecastAUPHAurinia Pharmaceuticals2.829 of 5 stars$12.22-0.4%$12.00-1.8%+81.5%$1.61B$235.13M28.42300Positive NewsCDTXCidara Therapeutics3.6184 of 5 stars$63.24-3.0%$64.14+1.4%+411.3%$1.60B$1.27M-5.6890Positive NewsWVEWAVE Life Sciences4.794 of 5 stars$9.74-0.2%$20.27+108.1%+76.8%$1.55B$108.30M-10.82240Positive NewsJANXJanux Therapeutics2.965 of 5 stars$25.53+1.7%$91.89+259.9%-47.1%$1.53B$10.59M-14.1830News CoverageSDGRSchrodinger3.1042 of 5 stars$20.05+3.5%$27.83+38.8%+2.3%$1.48B$207.54M-8.08790EWTXEdgewise Therapeutics2.3071 of 5 stars$14.00-1.1%$41.60+197.1%-23.2%$1.47BN/A-9.0360HROWHarrow3.5895 of 5 stars$38.32-1.3%$64.67+68.8%-8.4%$1.42B$199.61M-153.28180Analyst RevisionARDXArdelyx4.2076 of 5 stars$5.81-2.7%$11.50+97.9%-3.8%$1.40B$333.61M-25.2690Positive NewsETNB89BIO2.183 of 5 stars$9.44+2.3%$26.29+178.5%+6.5%$1.40BN/A-2.6140News CoverageAnalyst Forecast Related Companies and Tools Related Companies Immunocore Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives WAVE Life Sciences Alternatives Janux Therapeutics Alternatives Schrodinger Alternatives Edgewise Therapeutics Alternatives Harrow Alternatives Ardelyx Alternatives 89BIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access